[Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].

内科学 胃肠病学 医学 碱性磷酸酶 抗体 胆红素 丙氨酸转氨酶 肝功能
作者
C Y Huang,Y M Liu,H Liu,B Xu,H P Yan,H P Zhang,H Y Liao,X D Zhang,J Zhao,W J Li,Z P Duan
出处
期刊:Chinese Journal of Hepatology [Chinese Medical Association]
卷期号:30 (4): 419-425
标识
DOI:10.3760/cma.j.cn501113-20210501-00216
摘要

Objective: To analyze the clinical characteristics and prognostic value of liver function in a large samples of patients with anti-glycoprotein 210 (gp210 antibody) positive primary biliary cholangitis (PBC). Methods: A retrospective study was performed on 931 PBC cases in Beijing You'an Hospital affiliated to Capital Medical University from 2010 to 2019. According to the detection of gp210 antibody, 318 cases were divided into gp210 antibody positive group (positive group) and 613 cases were divided into gp210 antibody negative group (negative group). The differences in demographic, medical history, clinical indicators, B-ultrasound and pathological indicators as well as the histopathological basis were compared between the two groups. SPSS 16.0 software was used for statistical analysis. Measurement data were analyzed by t-test or rank sum test, and enumeration data by χ2 test. Multivariate analysis was used for logistic test, and and survival analysis was used for prognosis. Results: The positive and the negative groups were compared. The ratio of male to female was significantly higher in positive than negative group (1:5.35 vs. 1:9.73, P<0.05), and the difference was statistically significant. The proportion of hormone use in history of past diagnosed and treated was higher in positive than negative group (12.9% vs. 3.47%, P<0.05), and the difference was statistically significant. The detection of biochemical indexes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT) were higher in positive than the negative group (51.1 U/L vs. 41.1 U/L, 62.6 U/L vs. 49.6 U/L, 24.1 μmol/L vs. 17.9 μmol/L, 228.3 U/L vs. 169.6 U/L, 203.9 U/L vs. 147.6 U/L), (P<0.05), and the differences were statistically significant. Antinuclear antibody (ANA)-positive rate, high titer ratio and immunoglobulin G (IgG) levels were higher in positive than negative group (95.2% vs. 81.6%, 69.7% vs. 48.8%, 17.2 g/L vs. 16.2 g/L), (P<0.05), and the differences were statistically significant. The incidence of liver failure was higher in positive than negative group (P<0.05). CK7 and inflammation score were higher in positive group than negative group in liver histopathological observations (0.83±0.53 vs. 0.28±0.47; 1.06±0.39 vs. 0.54±0.65), (P<0.05), and the differences were statistically significant. Conclusion: The illness condition of patients with gp210 antibody positive PBC is more severe than patients with gp210 antibody negative PBC, and the incidence of liver failure is significantly increased. Cholangiocytes may be the histopathological basis of the clinical characteristics of gp210 antibody positive PBC patients.目的: 大样本分析抗糖蛋白210抗体(抗gp210抗体)阳性原发性胆汁性胆管炎(PBC)患者的临床特征及其对预后的影响。 方法: 回顾性研究首都医科大学附属北京佑安医院2010-2019年PBC患者931例。根据抗gp210抗体检测情况分为:抗gp210抗体阳性组(阳性组)318例和抗gp210抗体阴性组(阴性组)613例,比较两组之间的人口学、病史、临床指标、B超及病理指标间的差异,以及引起差异的病理性基础。应用SPSS 16.0软件进行统计分析,计量资料采用t检验或秩和检验,计数资料采用χ2检验,多因素分析采用logistics检验,预后采用生存分析。 结果: 阳性组与阴性组比较:阳性组男/女性别比例明显高于阴性组(1∶5.35对比1∶9.73,P<0.05);阳性组既往诊治病史激素应用比例高于阴性组(12.9%对比3.47%,P<0.05),差异均有统计学意义。阳性组生化学检测指标:丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBil)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)均高于阴性组(51.1 U/L对比41.1 U/L,62.6 U/L对比49.6 U/L,24.1 μmol/L对比17.9 μmol/L,228.3 U/L对比169.6 U/L,203.9 U/L对比147.6 U/L),P值均<0.05,差异均有统计学意义。阳性组抗核抗体阳性率、高滴度比例和免疫球蛋G水平均高于阴性组(95.2%对比81.6%,69.7%对比48.8%,17.2 g/L对比16.2 g/L),P值均<0.05,差异均有统计学意义;阳性组肝衰竭发生率高于阴性组(P<0.05);阳性组肝脏病理CK7评分和炎症评分高于阴性组(0.83±0.53对比0.28±0.47;1.06±0.39对比0.54±0.65,P值均<0.05),差异均有统计学意义。 结论: 抗gp210抗体阳性组PBC患者病情重于阴性组患者,并且肝衰竭发生率明显增多,肝细胞胆管化可能是抗gp210抗体阳性PBC患者临床特点病理基础。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乂氼完成签到 ,获得积分10
3秒前
HCT完成签到,获得积分10
6秒前
完美世界应助不安夏青采纳,获得10
8秒前
海英完成签到,获得积分10
11秒前
胜胜糖完成签到 ,获得积分10
13秒前
小陈老板完成签到 ,获得积分10
15秒前
skysleeper完成签到,获得积分0
17秒前
shacodow完成签到,获得积分10
22秒前
ll完成签到,获得积分10
24秒前
瞿人雄完成签到,获得积分10
26秒前
没心没肺完成签到,获得积分10
28秒前
28秒前
如意秋珊完成签到 ,获得积分10
31秒前
1002SHIB完成签到,获得积分10
31秒前
nihaolaojiu完成签到,获得积分10
32秒前
sheetung完成签到,获得积分10
32秒前
麦田麦兜完成签到,获得积分10
33秒前
chongya发布了新的文献求助10
36秒前
myq完成签到 ,获得积分10
40秒前
善善完成签到 ,获得积分10
42秒前
浮游应助chongya采纳,获得10
43秒前
学问完成签到,获得积分10
44秒前
叶痕TNT完成签到 ,获得积分10
45秒前
赘婿应助藏藏采纳,获得10
55秒前
sciforce完成签到,获得积分10
59秒前
孟寐以求完成签到 ,获得积分10
1分钟前
熊泰山完成签到 ,获得积分10
1分钟前
是真的完成签到 ,获得积分10
1分钟前
悦耳的城完成签到 ,获得积分10
1分钟前
mojito完成签到 ,获得积分10
1分钟前
可夫司机完成签到 ,获得积分10
1分钟前
回首不再是少年完成签到,获得积分0
1分钟前
果粒橙完成签到 ,获得积分10
1分钟前
害羞的雁易完成签到 ,获得积分10
1分钟前
1分钟前
黙宇循光完成签到 ,获得积分10
1分钟前
不安夏青发布了新的文献求助10
1分钟前
ziyan完成签到 ,获得积分10
1分钟前
煌大河完成签到 ,获得积分10
1分钟前
胡图图完成签到 ,获得积分10
1分钟前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Hydrothermal Circulation and Seawater Chemistry: Links and Feedbacks 1200
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5149855
求助须知:如何正确求助?哪些是违规求助? 4345756
关于积分的说明 13530839
捐赠科研通 4188229
什么是DOI,文献DOI怎么找? 2296728
邀请新用户注册赠送积分活动 1297144
关于科研通互助平台的介绍 1241507